In-stent restenosis (ISR) remains a significant clinical problem in patients with coronary artery disease treated with percutaneous coronary intervention. Decreased serum albumin (SA) level is related to an increased risk of cardiovascular events. The aim of the present study was to assess whether SA levels at admission are an independent predictor of ISR in patients undergoing bare-metal stent (BMS) implantation. A total of 341 patients (aged 61 ± 11, 65.4% men) with a history of BMS implantation and a further control coronary angiography due to stable angina pectoris (SAP) were included. The study population was classified into 2 groups: patients with and without ISR. The ISR was observed in 140 (41.1%) patients. We found significantly lower SA levels in patients who developed ISR than in those who did not (3.69 ± 0.41 vs 4.07 ± 0.35 mg/dL, P < .001). Multivariate analysis revealed that SA level (odds ratio 0.109, 95% confidence interval 0.017-0.700, P = .020), stent diameter, reason for stent implantation, and body mass index were independent risk factors for the development of ISR. The SA level at admission is inversely associated with ISR in patients with SAP.
CarubaTKatsahianSSchrammC. Treatment for stable coronary artery disease: a network meta-analysis of cost-effectiveness studies. PLoS One. 2014;9(6):e98371.
2.
YinRXYangDZWuJZ. Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis. Theranostics. 2014;4(2):175–200.
3.
NiccoliGMontoneRAFerranteGCreaF. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol. 2010;56(22):1783–1793.
4.
InoueTNodeK. Molecular basis of restenosis and novel issues of drug eluting stents. Circ J. 2009;73(4):615–621.
5.
WeltFGRogersC. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22(11):1769–1776.
6.
FarbAWeberDKKolodgieFDBurkeAPVirmaniR. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105(25):2974–2980.
7.
PetersTJr. Serum albumin. Adv Protein Chem. 1985;37:161–245.
8.
CurcioATorellaDIndolfiC. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J. 2011;75(6):1287–1296.
9.
DonBRKaysenG. Serum albumin: relationship to inflammation and nutrition. Semin Dial. 2004;17(6):432–437.
10.
ZoellnerHHoflerMBeckmannR. Serum albumin is a specific inhibitor of apoptosis in human endothelial cells. J Cell Sci. 1996;109(pt 10):2571–2580.
11.
ZhangWJFreiB. Albumin selectively inhibits TNF alpha-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells. Cardiovasc Res. 2002;55(4):820–829.
12.
JolesJAWillekes-KoolschijnNKoomansHA. Hypoalbuminemia causes high blood viscosity by increasing red cell lysophosphatidylcholine. Kidney Int. 1997;52(3):761–770.
13.
HalliwellB. Albumin—an important extracellular antioxidant?Biochem Pharmacol. 1988;37(4):569–571.
14.
RocheMRondeauPSinghNRTarnusEBourdonE. The antioxidant properties of serum albumin. FEBS Lett. 2008;582(13):1783–1787.
15.
GreselePDeckmynHHuybrechtsEVermylenJ. Serum Albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2. Biochem Pharmacol. 1984;33(13):2083–2088.
16.
GoldwasserPFeldmanJ. Association of serum albumin and mortality risk. J Clin Epidemiol. 1997;50(6):693–703.
17.
WeijenbergMPFeskensEJSouverijnJHKromhoutD. Serum albumin, coronary heart disease risk, and mortality in an elderly cohort. Epidemiology. 1997;8(1):87–92.
18.
MikhailidisDPGanotakisES. Plasma albumin and platelet function: relevance to atherogenesis and thrombosis. Platelets.1996;7(3):125–137.
19.
MuratSNKurtulAYarliogluesM. Impact of serum albumin levels on contrast induced acute kidney injury in patients with acute coronary syndromes treated with percutaneous coronary intervention. Angiology. 2015;66(8):732–737.
20.
SchalkBWVisserMBremmerMAPenninxBWBouterLMDeegDJ. Change of serum albumin and risk of cardiovascular disease and all-cause mortality: Longitudinal Aging Study Amsterdam. Am J Epidemiol. 2006;164(10):969–977.
21.
HorwichTBKalantar-ZadehKMacLellanRWFonarowGC. Albumin levels predict survival in patients with systolic heart failure. Am Heart J. 2008;155(5):883–889.
22.
SugiharaMMiuraSNishikawaH. Characteristics of patients and types of lesions in patients with drug-eluting or bare-metal stent implantation in small coronary arteries: from the FU-Registry. J Cardiol. 2013;61(12):117–121.
23.
SchieleTM.Current understanding of coronary in-stent restenosis. Pathophysiology, clinical presentation, diagnostic work-up, and management. Z Kardiol. 2005;94(11):772–790.
24.
GürmenTBabalıkEGülbaranMÖztürkSÖztürkM. Intracoronary stent implantation: six months results, predictors of stent restenosis. Arch Turk Soc Cardiol. 1998;26(7):408.
25.
KatoTSKitadaSYangJ. Relation of preoperative serum albumin levels to survival in patients undergoing left ventricular assist device implantation. Am J Cardiol. 2013;112(9):1484–1488.
26.
OduncuVErkolAKarabayCY. The prognostic value of serum albumin levels on admission in patients with acute ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention. Coron Artery Dis. 2013;24(2):88–94.
27.
KurtulAMuratSNYarliogluesM. Usefulness of serum albumin concentration to predict high coronary SYNTAX score and in-hospital mortality in patients with acute coronary syndrome. Angiology. 2016;67(1):34–40.
28.
TurakOOzcanFIsleyenA. Usefulness of the neutrophil-to-lymphocyte ratio to predict bare-metal stent restenosis. Am J Cardiol. 2012;110(10):1405–1410.
29.
KurtulAMuratSNYarliogluesM. The association of red cell distribution width with in-stent restenosis in patients with stable coronary artery disease. Platelets. 2015;26(1):48–52.
30.
FerranteGNiccoliGBiasucciLM. Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. Cardiovasc Revasc Med. 2008;9(3):156–165.
31.
NunesGLAbizaidACTheodoroMP. Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: a randomized study. Am Heart J. 2006;152(5):914.e1–e7.
32.
TurakOCanpolatUÖzcanF. Usefulness of preprocedural serum uric acid level to predict restenosis of bare metal stents. Am J Cardiol. 2014;113(2):197–202.
